Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2516, 2011. ,
DOI : 10.1056/NEJMoa1103782
Dermatologic manifestations of cytotoxic therapy, Dermatologic Therapy, vol.139, issue.3, pp.401-410, 2011. ,
DOI : 10.1111/j.1529-8019.2011.01432.x
Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review, Psycho-Oncology, vol.15, issue.4, pp.317-328, 2008. ,
DOI : 10.1002/pon.1245
Onycholysis Associated with Weekly Administration of Paclitaxel, Annals of Pharmacotherapy, vol.86, issue.5, pp.584-586, 1999. ,
DOI : 10.1007/BF00192885
Frequency and characteristics of docetaxel-induced radiation recall phenomenon, International Journal of Radiation Oncology*Biology*Physics, vol.66, issue.4, pp.1187-1191, 2006. ,
DOI : 10.1016/j.ijrobp.2006.05.073
Adriamycin-induced recall phenomenon 15 years after radiotherapy, JAMA: The Journal of the American Medical Association, vol.239, issue.10, p.931, 1978. ,
DOI : 10.1001/jama.239.10.931b
Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib, Oncology, vol.77, issue.5, pp.257-271, 2009. ,
DOI : 10.1159/000258880
Capecitabine and hand???foot syndrome, Expert Opinion on Drug Safety, vol.13, issue.12, pp.159-169, 2011. ,
DOI : 10.1093/annonc/mdp047
Neutrophilic eccrine hidradenitis, Clinics in Dermatology, vol.18, issue.3, pp.319-330, 2000. ,
DOI : 10.1016/S0738-081X(99)00123-6
Neutrophilic eccrine hidradenitis induced by granulocyte colony-stimulating factor, British Journal of Dermatology, vol.5, issue.2, pp.354-355, 1998. ,
DOI : 10.1001/archderm.130.1.77
Toxic erythema of chemotherapy: A useful clinical term, Journal of the American Academy of Dermatology, vol.59, issue.3, pp.524-529, 2008. ,
DOI : 10.1016/j.jaad.2008.05.018
Persistent serpentine supravenous hyperpigmented eruption as an adverse reaction to chemotherapy combining actinomycin and vincristine, Journal of the American Academy of Dermatology, vol.43, issue.3, pp.540-546, 2000. ,
DOI : 10.1067/mjd.2000.106239
Cyclophosphamide-induced nail discoloration and skin hyperpigmentation: a rare presentation, Clinical and Experimental Dermatology, vol.60, issue.3, pp.405-406, 2009. ,
DOI : 10.1111/j.1365-2230.2008.02896.x
Ifosfamide-induced hyperpigmentation, Cancer, vol.47, issue.9, pp.2873-2875, 1993. ,
DOI : 10.1002/1097-0142(19930501)71:9<2873::AID-CNCR2820710931>3.0.CO;2-6
Ultraviolet recall reaction after total body irradiation, etoposide, and methotrexate therapy, Journal of the American Academy of Dermatology, vol.56, issue.3, pp.494-499, 2007. ,
DOI : 10.1016/j.jaad.2006.11.009
Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine, Journal of the American Academy of Dermatology, vol.59, issue.2, pp.4-6, 2008. ,
DOI : 10.1016/j.jaad.2007.06.040
Flagellate Hyperpigmentation Following Intralesional Bleomycin Treatment of Verruca Plantaris, Archives of Dermatology, vol.139, issue.3, pp.337-339, 2003. ,
DOI : 10.1001/archderm.139.3.337
Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin, Journal of Cutaneous Pathology, vol.56, issue.6, pp.591-595, 2003. ,
DOI : 10.1006/jmcc.1996.0186
Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors], Ann Dermatol Venereol Spec No, vol.1, pp.16-24, 2008. ,
Hyperactive Ras in developmental disorders and cancer, Nature Reviews Cancer, vol.91, issue.4, pp.295-308, 2007. ,
DOI : 10.1038/nrc2109
Cutaneous side-effects of kinase inhibitors and blocking antibodies, The Lancet Oncology, vol.6, issue.7, pp.491-500, 2005. ,
DOI : 10.1016/S1470-2045(05)70243-6
Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management, Journal of the American Academy of Dermatology, vol.56, issue.2, pp.317-326, 2007. ,
DOI : 10.1016/j.jaad.2006.09.005
Dermatologic symptoms associated with the multikinase inhibitor sorafenib, Journal of the American Academy of Dermatology, vol.60, issue.2, pp.299-305, 2009. ,
DOI : 10.1016/j.jaad.2008.06.034
Effets indésirables dermatologiques des thérapies ciblées antiangiogéniques, Bull Cancer, vol.98, pp.1221-1229, 2011. ,
Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management, Journal of the European Academy of Dermatology and Venereology, vol.26, issue.Suppl. 5, pp.11-18, 2013. ,
DOI : 10.1111/j.1468-3083.2012.04546.x
Cutaneous effects of BRAF inhibitor therapy: a case series, Annals of Oncology, vol.24, issue.2, pp.530-537, 2013. ,
DOI : 10.1093/annonc/mds292
Appearance of skin and nail toxicity in patients with breast cancer who underwent trastuzumab-containing chemotherapyGan To Kagaku Ryoho, pp.1453-1459, 2011. ,
Nail toxicity associated with epidermal growth??factor receptor inhibitor therapy, Journal of the American Academy of Dermatology, vol.56, issue.3, pp.460-465, 2007. ,
DOI : 10.1016/j.jaad.2006.09.013
Epidermal growth factor receptor inhibitors: A new era of drug reactions in a new era of cancer therapy, Journal of the American Academy of Dermatology, vol.56, issue.3, pp.514-521, 2007. ,
DOI : 10.1016/j.jaad.2006.11.004
Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor, Archives of Dermatology, vol.144, issue.7, pp.886-892, 2008. ,
DOI : 10.1001/archderm.144.7.886
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma, British Journal of Dermatology, vol.230, issue.Suppl., 2012. ,
DOI : 10.1111/j.1365-2133.2012.11155.x
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma, New England Journal of Medicine, vol.366, issue.23, pp.2171-2180, 2012. ,
DOI : 10.1056/NEJMoa1113713
Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib, Journal of Clinical Oncology, vol.27, issue.23, pp.59-61, 2009. ,
DOI : 10.1200/JCO.2009.23.4823
Survival in BRAF V600???Mutant Advanced Melanoma Treated with Vemurafenib, New England Journal of Medicine, vol.366, issue.8, 2012. ,
DOI : 10.1056/NEJMoa1112302
Cutaneous effects of BRAF inhibitor therapy: a case series, Annals of Oncology, vol.24, issue.2, pp.530-537, 2013. ,
DOI : 10.1093/annonc/mds292
Camps-Herrero C Cutaneous toxicity associated with cetuximab treatment in metastatic colorectal cancer].Farm Hosp, pp.114-134, 2011. ,
Dermatologic symptoms associated with the multikinase inhibitor sorafenib, Journal of the American Academy of Dermatology, vol.60, issue.2, pp.299-305, 2009. ,
DOI : 10.1016/j.jaad.2008.06.034
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients, Annals of Oncology, vol.24, issue.6, pp.1691-1697, 2013. ,
DOI : 10.1093/annonc/mdt015
Appearance of skin and nail toxicity in patients with breast cancer who underwent trastuzumab-containing chemotherapy], Gan To Kagaku Ryoho, vol.38, pp.1453-1456, 2011. ,
Effets ind??sirables cutan??s et retentissement sur la qualit?? de vie des inhibiteurs de mTOR au cours du traitement du cancer du rein, Annales de Dermatologie et de V??n??r??ologie, vol.140, issue.5, pp.353-362, 2013. ,
DOI : 10.1016/j.annder.2013.02.023
Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany, Dermatology, vol.216, issue.4, pp.366-372, 2008. ,
DOI : 10.1159/000119415
Psychometric Properties of the Beck Depression Inventory???II in Low-Income, African American Suicide Attempters, Journal of Personality Assessment, vol.44, issue.5, pp.521-523, 2008. ,
DOI : 10.1037/1040-3590.7.4.472
BRAF Inhibitor Unveils Its Potential against Advanced Melanoma, Cancer Cell, vol.18, issue.4, pp.301-302, 2010. ,
DOI : 10.1016/j.ccr.2010.10.001
URL : http://doi.org/10.1016/j.ccr.2010.10.001
Cutaneous toxicities of RAF inhibitors, The Lancet Oncology, vol.14, issue.1, pp.11-18, 2013. ,
DOI : 10.1016/S1470-2045(12)70413-8
Cetuximab-induced cutaneous toxicity, Journal of the European Academy of Dermatology and Venereology, vol.13, issue.suppl 2, pp.692-696, 2010. ,
DOI : 10.1111/j.1468-3083.2009.03490.x
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors, Annals of Oncology, vol.16, issue.9, pp.1425-1433, 2005. ,
DOI : 10.1093/annonc/mdi279
Epidermal growth factor receptor inhibitors: A new era of drug reactions in a new era of cancer therapy, Journal of the American Academy of Dermatology, vol.56, issue.3, pp.514-517, 2007. ,
DOI : 10.1016/j.jaad.2006.11.004
Prevention of chemotherapy-induced hair loss by scalp cooling, Annals of Oncology, vol.16, issue.3, pp.352-358, 2005. ,
DOI : 10.1093/annonc/mdi088
Nail Toxicity Induced by Cancer Chemotherapy, Journal of Oncology Pharmacy Practice, vol.112, issue.3, pp.143-155, 2009. ,
DOI : 10.1177/1078155208100450
Compliance and Effective Management of the Hand-Foot Syndrome in Colon Cancer Patients Receiving Capecitabine as Adjuvant Chemotherapy, Yonsei Medical Journal, vol.50, issue.6, pp.796-802, 2009. ,
DOI : 10.3349/ymj.2009.50.6.796
Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study, Journal of the American Academy of Dermatology, vol.67, issue.6, pp.1265-1272, 2012. ,
DOI : 10.1016/j.jaad.2012.04.008
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.31, issue.26, pp.3205-3211, 2013. ,
DOI : 10.1200/JCO.2013.49.8691
Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma, The Oncologist, vol.18, issue.3, pp.314-322, 2013. ,
DOI : 10.1634/theoncologist.2012-0333
RAF inhibition and induction of cutaneous squamous cell carcinoma, Current Opinion in Oncology, vol.23, issue.2, pp.177-182, 2011. ,
DOI : 10.1097/CCO.0b013e3283436e8c
Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors, New England Journal of Medicine, vol.366, issue.3, pp.207-215, 2012. ,
DOI : 10.1056/NEJMoa1105358
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, vol.50, issue.7287, pp.431-435, 2010. ,
DOI : 10.1038/nature08833
A broad spectrum of human papillomavirus types is present in the skin of Australian patients with non-melanoma skin cancers and solar keratosis, British Journal of Dermatology, vol.80, issue.1, pp.64-73, 2003. ,
DOI : 10.1046/j.1365-2133.1999.02972.x
Skin autografts in epidermodysplasia verruciformis: human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion, Cancer Res, vol.57, pp.4214-4216, 1997. ,
Vemurafenib Cooperates with HPV to Promote Initiation of Cutaneous Tumors, Cancer Research, vol.74, issue.8, 2014. ,
DOI : 10.1158/0008-5472.CAN-13-1065-T
Cutaneous side effects of inhibitors of the RAS, ERK signalling pathway and their management ,
Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib, J Clin Aesthet Dermatol, vol.6, pp.27-37, 2013. ,
Dynamic Changes in Nevi of a Patient With Melanoma Treated With Vemurafenib, Archives of Dermatology, vol.148, issue.10, pp.1183-1185, 2012. ,
DOI : 10.1001/archdermatol.2012.2649
N??vus ??ruptifs sous soraf??nib, Annales de Dermatologie et de V??n??r??ologie, vol.135, issue.10, pp.672-674, 2008. ,
DOI : 10.1016/j.annder.2008.04.016
Inhibition, Journal of Clinical Oncology, vol.30, issue.19, pp.2375-2383, 2012. ,
DOI : 10.1200/JCO.2011.41.1660
Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice, Cancer Cell, vol.15, issue.4, pp.294-303, 2009. ,
DOI : 10.1016/j.ccr.2009.02.022
Second primary melanomas treated with BRAF blockers: study by reflectance confocal microscopy, British Journal of Dermatology, vol.27, issue.6, pp.1230-1235, 2013. ,
DOI : 10.1111/bjd.12210
Vemurafenib in melanoma with BRAF V600E mutation, N. Engl. J. Med, vol.365, pp.1448-1449, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00790751
Vemurafenib: an unusual UVA-induced photosensitivity, Experimental Dermatology, vol.26, issue.4, pp.297-298, 2013. ,
DOI : 10.1111/exd.12119
mutation, Future Oncology, vol.8, issue.5, pp.499-507, 2012. ,
DOI : 10.2217/fon.12.43
Ultraviolet A and Photosensitivity during Vemurafenib Therapy, New England Journal of Medicine, vol.366, issue.5, pp.480-481, 2012. ,
DOI : 10.1056/NEJMc1113752
Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic, American Journal of Clinical Dermatology, vol.46, issue.13, pp.327-333, 2013. ,
DOI : 10.1007/s40257-013-0021-0
Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors, British Journal of Dermatology, vol.25, issue.3, pp.515-521, 2009. ,
DOI : 10.1111/j.1365-2133.2009.09214.x
HFS-14, a Specific Quality of Life Scale Developed for Patients Suffering from Hand-Foot Syndrome, The Oncologist, vol.16, issue.10, pp.1469-1478, 2011. ,
DOI : 10.1634/theoncologist.2011-0033
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study, The Lancet Oncology, vol.7, issue.11, pp.903-909, 2006. ,
DOI : 10.1016/S1470-2045(06)70910-X